In its second deal with Novartis AG of the past 11 months, Monte Rosa Therapeutics Inc. is getting $120 million up front to collaborate on developing molecular glue degraders to treat immune-mediated diseases. The agreement could swell to $5.7 billion for Monte Rosa.
Tuojie Biotech (Shanghai) Co. Ltd. has described apelin receptor (APLNR) agonists reported to be useful for the treatment of neurological disorders, cardiovascular disorders, obesity, diabetes, chronic kidney diseases and diabetic nephropathy.
Ono Pharmaceutical Co. Ltd. and Wuxi Apptec Co. Ltd. have divulged sphingosine 1-phosphate S1P3 receptor antagonists reported to be useful for the treatment of cancer, liver diseases, neurodegeneration, and metabolic, endocrine, cardiovascular and respiratory disorders.
Haisco Pharmaceutical Group Co. Ltd. has identified pyridone derivatives acting as integrin α4β7 (LPAM-1) antagonists reported to be useful for the treatment of Crohn’s disease and ulcerative colitis.
China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has synthesized tricyclic heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Scientists at Gwangju Institute of Science & Technology and JD Bioscience Inc. have disclosed 5-HT2A receptor antagonists reported to be useful for the treatment of cancer, hyperlipidemia, obesity, diabetes, arteriosclerosis, hepatic steatosis, fibrosis and hypertension.
FMS-like tyrosine kinase 3 (FLT3) mutations, particularly internal tandem duplications and point mutations in the tyrosine kinase domain, are frequently observed in acute myeloid leukemia (AML) and contribute to disease progression and poor prognosis.
Auravax Therapeutics Inc. has received funding from the Gates Foundation to evaluate the efficacy of Nanosting-001 in validated swine models of influenza infection at Kansas State University College of Veterinary Medicine and The Pirbright Institute.
Mutations in the isocitrate dehydrogenase enzymes IDH1 and IDH2 have been associated with oncogenic transformation in several malignancies, including gliomas, acute myeloid leukemia (AML), cholangiocarcinoma and chondrosarcomas. Despite the approval of several mIDH1 inhibitors, suboptimal blood-brain barrier penetration and the development of acquired resistance limit their use.
Cantoni Therapeutics BV has announced the closing of additional financing to advance its lead asset into IND-enabling studies for obesity and its comorbidities. The company is developing small-molecule inhibitors of nicotinamide N-methyltransferase (NNMT), a promising target for cardiometabolic diseases. Cantoni has also won a Novo Nordisk ValidatioNN grant supporting translational research work on the mode of action of NNMT inhibition.
RSS
